Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6805d20527de2-trace').style.display = (document.getElementById('cakeErr6805d20527de2-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6805d20527de2-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6805d20527de2-code').style.display = (document.getElementById('cakeErr6805d20527de2-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6805d20527de2-context').style.display = (document.getElementById('cakeErr6805d20527de2-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6805d20527de2-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6805d20527de2-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 19605,
		&#039;title&#039; =&gt; &#039;Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;
&lt;br /&gt;
IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;
&lt;br /&gt;
In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;
&lt;br /&gt;
A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;
&lt;br /&gt;
The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;
&lt;br /&gt;
The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;
&lt;br /&gt;
However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;
&lt;br /&gt;
The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;
&lt;br /&gt;
IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 5 March, 2013, http://www.business-standard.com/article/companies/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-113030500026_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 19743,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 19605,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;&lt;br /&gt;IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;&lt;br /&gt;In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;&lt;br /&gt;Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;&lt;br /&gt;A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;&lt;br /&gt;The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;&lt;br /&gt;The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;&lt;br /&gt;However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;&lt;br /&gt;The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;&lt;br /&gt;IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;&lt;br /&gt;Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 19605,
	&#039;title&#039; =&gt; &#039;Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;
&lt;br /&gt;
IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;
&lt;br /&gt;
In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;
&lt;br /&gt;
A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;
&lt;br /&gt;
The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;
&lt;br /&gt;
The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;
&lt;br /&gt;
However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;
&lt;br /&gt;
The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;
&lt;br /&gt;
IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 5 March, 2013, http://www.business-standard.com/article/companies/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-113030500026_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 19743,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 19605
$metaTitle = &#039;LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;
$metaKeywords = &#039;medicines,patents,Cancer,Health&#039;
$metaDesc = &#039;
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;&lt;br /&gt;IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;&lt;br /&gt;In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;&lt;br /&gt;Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;&lt;br /&gt;A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;&lt;br /&gt;The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;&lt;br /&gt;The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;&lt;br /&gt;However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;&lt;br /&gt;The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;&lt;br /&gt;IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;&lt;br /&gt;Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug | Im4change.org</title>
    <meta name="description" content="
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Bayer plea dismissed, Natco allowed to sell patent cancer drug</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard<br /><br /><em>Chennai: </em>The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.<br /><br />IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.<br /><br />In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.<br /><br />Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority's decision. On September 17, the board had dismissed a stay petition filed by Bayer.<br /><br />A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.<br /><br />The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.<br /><br />The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.<br /><br />However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&quot; said Sridevan.<br /><br />The coram dismissed Bayer's arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.<br /><br />IPAB also rejected Bayer's contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.<br /><br />Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller's compulsory licensing conditions by Natco.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6805d20527de2-trace').style.display = (document.getElementById('cakeErr6805d20527de2-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6805d20527de2-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6805d20527de2-code').style.display = (document.getElementById('cakeErr6805d20527de2-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6805d20527de2-context').style.display = (document.getElementById('cakeErr6805d20527de2-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6805d20527de2-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6805d20527de2-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 19605,
		&#039;title&#039; =&gt; &#039;Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;
&lt;br /&gt;
IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;
&lt;br /&gt;
In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;
&lt;br /&gt;
A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;
&lt;br /&gt;
The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;
&lt;br /&gt;
The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;
&lt;br /&gt;
However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;
&lt;br /&gt;
The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;
&lt;br /&gt;
IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 5 March, 2013, http://www.business-standard.com/article/companies/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-113030500026_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 19743,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 19605,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;&lt;br /&gt;IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;&lt;br /&gt;In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;&lt;br /&gt;Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;&lt;br /&gt;A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;&lt;br /&gt;The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;&lt;br /&gt;The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;&lt;br /&gt;However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;&lt;br /&gt;The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;&lt;br /&gt;IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;&lt;br /&gt;Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 19605,
	&#039;title&#039; =&gt; &#039;Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;
&lt;br /&gt;
IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;
&lt;br /&gt;
In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;
&lt;br /&gt;
A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;
&lt;br /&gt;
The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;
&lt;br /&gt;
The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;
&lt;br /&gt;
However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;
&lt;br /&gt;
The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;
&lt;br /&gt;
IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 5 March, 2013, http://www.business-standard.com/article/companies/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-113030500026_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 19743,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 19605
$metaTitle = &#039;LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;
$metaKeywords = &#039;medicines,patents,Cancer,Health&#039;
$metaDesc = &#039;
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;&lt;br /&gt;IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;&lt;br /&gt;In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;&lt;br /&gt;Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;&lt;br /&gt;A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;&lt;br /&gt;The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;&lt;br /&gt;The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;&lt;br /&gt;However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;&lt;br /&gt;The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;&lt;br /&gt;IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;&lt;br /&gt;Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug | Im4change.org</title>
    <meta name="description" content="
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Bayer plea dismissed, Natco allowed to sell patent cancer drug</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard<br /><br /><em>Chennai: </em>The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.<br /><br />IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.<br /><br />In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.<br /><br />Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority's decision. On September 17, the board had dismissed a stay petition filed by Bayer.<br /><br />A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.<br /><br />The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.<br /><br />The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.<br /><br />However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&quot; said Sridevan.<br /><br />The coram dismissed Bayer's arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.<br /><br />IPAB also rejected Bayer's contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.<br /><br />Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller's compulsory licensing conditions by Natco.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6805d20527de2-trace').style.display = (document.getElementById('cakeErr6805d20527de2-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6805d20527de2-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6805d20527de2-code').style.display = (document.getElementById('cakeErr6805d20527de2-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6805d20527de2-context').style.display = (document.getElementById('cakeErr6805d20527de2-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6805d20527de2-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6805d20527de2-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 19605,
		&#039;title&#039; =&gt; &#039;Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;
&lt;br /&gt;
IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;
&lt;br /&gt;
In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;
&lt;br /&gt;
A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;
&lt;br /&gt;
The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;
&lt;br /&gt;
The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;
&lt;br /&gt;
However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;
&lt;br /&gt;
The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;
&lt;br /&gt;
IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 5 March, 2013, http://www.business-standard.com/article/companies/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-113030500026_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 19743,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 19605,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;&lt;br /&gt;IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;&lt;br /&gt;In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;&lt;br /&gt;Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;&lt;br /&gt;A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;&lt;br /&gt;The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;&lt;br /&gt;The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;&lt;br /&gt;However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;&lt;br /&gt;The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;&lt;br /&gt;IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;&lt;br /&gt;Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 19605,
	&#039;title&#039; =&gt; &#039;Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;
&lt;br /&gt;
IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;
&lt;br /&gt;
In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;
&lt;br /&gt;
A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;
&lt;br /&gt;
The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;
&lt;br /&gt;
The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;
&lt;br /&gt;
However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;
&lt;br /&gt;
The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;
&lt;br /&gt;
IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 5 March, 2013, http://www.business-standard.com/article/companies/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-113030500026_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 19743,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 19605
$metaTitle = &#039;LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug&#039;
$metaKeywords = &#039;medicines,patents,Cancer,Health&#039;
$metaDesc = &#039;
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Chennai: &lt;/em&gt;The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.&lt;br /&gt;&lt;br /&gt;IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.&lt;br /&gt;&lt;br /&gt;In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.&lt;br /&gt;&lt;br /&gt;Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority&#039;s decision. On September 17, the board had dismissed a stay petition filed by Bayer.&lt;br /&gt;&lt;br /&gt;A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.&lt;br /&gt;&lt;br /&gt;The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.&lt;br /&gt;&lt;br /&gt;The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.&lt;br /&gt;&lt;br /&gt;However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &amp;quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&amp;quot; said Sridevan.&lt;br /&gt;&lt;br /&gt;The coram dismissed Bayer&#039;s arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.&lt;br /&gt;&lt;br /&gt;IPAB also rejected Bayer&#039;s contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.&lt;br /&gt;&lt;br /&gt;Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller&#039;s compulsory licensing conditions by Natco.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug | Im4change.org</title>
    <meta name="description" content="
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Bayer plea dismissed, Natco allowed to sell patent cancer drug</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard<br /><br /><em>Chennai: </em>The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.<br /><br />IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.<br /><br />In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.<br /><br />Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority's decision. On September 17, the board had dismissed a stay petition filed by Bayer.<br /><br />A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.<br /><br />The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.<br /><br />The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.<br /><br />However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&quot; said Sridevan.<br /><br />The coram dismissed Bayer's arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.<br /><br />IPAB also rejected Bayer's contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.<br /><br />Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller's compulsory licensing conditions by Natco.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 19605,
		'title' => 'Bayer plea dismissed, Natco allowed to sell patent cancer drug',
		'subheading' => '',
		'description' => '<div align="justify">
-The Business Standard<br />
<br />
<em>Chennai: </em>The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.<br />
<br />
IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.<br />
<br />
In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.<br />
<br />
Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority's decision. On September 17, the board had dismissed a stay petition filed by Bayer.<br />
<br />
A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.<br />
<br />
The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.<br />
<br />
The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.<br />
<br />
However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&quot; said Sridevan.<br />
<br />
The coram dismissed Bayer's arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.<br />
<br />
IPAB also rejected Bayer's contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.<br />
<br />
Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller's compulsory licensing conditions by Natco.
</div>',
		'credit_writer' => 'The Business Standard, 5 March, 2013, http://www.business-standard.com/article/companies/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-113030500026_1.html',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 19743,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 19605,
	'metaTitle' => 'LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug',
	'metaKeywords' => 'medicines,patents,Cancer,Health',
	'metaDesc' => '
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in...',
	'disp' => '<div align="justify">-The Business Standard<br /><br /><em>Chennai: </em>The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.<br /><br />IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.<br /><br />In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.<br /><br />Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority's decision. On September 17, the board had dismissed a stay petition filed by Bayer.<br /><br />A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.<br /><br />The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.<br /><br />The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.<br /><br />However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&quot; said Sridevan.<br /><br />The coram dismissed Bayer's arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.<br /><br />IPAB also rejected Bayer's contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.<br /><br />Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller's compulsory licensing conditions by Natco.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 19605,
	'title' => 'Bayer plea dismissed, Natco allowed to sell patent cancer drug',
	'subheading' => '',
	'description' => '<div align="justify">
-The Business Standard<br />
<br />
<em>Chennai: </em>The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.<br />
<br />
IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.<br />
<br />
In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.<br />
<br />
Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority's decision. On September 17, the board had dismissed a stay petition filed by Bayer.<br />
<br />
A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.<br />
<br />
The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.<br />
<br />
The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.<br />
<br />
However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&quot; said Sridevan.<br />
<br />
The coram dismissed Bayer's arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.<br />
<br />
IPAB also rejected Bayer's contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.<br />
<br />
Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller's compulsory licensing conditions by Natco.
</div>',
	'credit_writer' => 'The Business Standard, 5 March, 2013, http://www.business-standard.com/article/companies/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-113030500026_1.html',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-19743',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 19743,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 19605
$metaTitle = 'LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug'
$metaKeywords = 'medicines,patents,Cancer,Health'
$metaDesc = '
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in...'
$disp = '<div align="justify">-The Business Standard<br /><br /><em>Chennai: </em>The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.<br /><br />IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.<br /><br />In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.<br /><br />Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority's decision. On September 17, the board had dismissed a stay petition filed by Bayer.<br /><br />A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.<br /><br />The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.<br /><br />The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.<br /><br />However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. &quot;We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant,&quot; said Sridevan.<br /><br />The coram dismissed Bayer's arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.<br /><br />IPAB also rejected Bayer's contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.<br /><br />Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller's compulsory licensing conditions by Natco.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Bayer plea dismissed, Natco allowed to sell patent cancer drug

-The Business Standard Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India. IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement. In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price. Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority's decision. On September 17, the board had dismissed a stay petition filed by Bayer. A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision. The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price. The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said. However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. "We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant," said Sridevan. The coram dismissed Bayer's arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug. IPAB also rejected Bayer's contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing. Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller's compulsory licensing conditions by Natco.